Aurobindo Pharma Ltd has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin injections.
Nafcillin for injection is a sterile semisynthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
It may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results.
The products were ready for launch, the Hyderabad-based company said in a release.